Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Momentum

Twist Bioscience Corporation’s stocks have been trading up by 11.52 percent following transformative gene-synthesis innovation momentum.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Shares of TWST climbed between about 1.5% and more than 4% after the company announced a new data services agreement with Eli Lilly’s AI-driven TuneLab platform.
The Lilly TuneLab deal plugs Twist Bioscience’s antibody characterization and wet-lab data directly into Lilly’s AI/ML drug discovery models, reinforcing TWST’s role in AI-enabled biotech.
TWST posted Q3 FY26 revenue of $118.4M, up more than 23% year over year, with gross margin at 52.8%, raised full-year guidance to $456–457M, and reaffirmed adjusted EBITDA breakeven for Q4 FY26.
UBS started coverage on Twist Bioscience with a Neutral rating but a hefty $144 price target, well above the current analyst mean target of $87.56 and against an overall Buy consensus.
Management confirmed that AI mini-binder work with Anthropic is “probably” already baked into TWST’s 2027 orders outlook, limiting surprise upside from that specific project.

Live Update At 12:32:50 EDT: On Thursday, September 17, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 11.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience, trading as TWST, is starting to look less like a speculative story and more like a real business turning the corner. In Q3 FY26, Twist Bioscience reported $118.4M in revenue, growing more than 23% year over year and marking 14 straight quarters of top-line growth. That kind of streak matters for traders because it shows demand is not a one-quarter fluke.

Gross margin at Twist Bioscience has climbed to 52.8%, a big deal in a tools-style “picks-and-shovels” name. High gross margin gives TWST more room to scale into profitability as operating costs get spread over a larger revenue base. The company raised full-year revenue guidance to $456–457M and reiterated a target to hit adjusted EBITDA breakeven in Q4 FY26. That tells traders the profitability inflection is not just talk.

More Breaking News

The balance sheet behind TWST is reasonably solid. With a current ratio of 2.7 and total debt to equity of 0.24, Twist Bioscience has liquidity and modest leverage, useful in a volatile market. Yes, margins at the EBIT and net level are still negative, but the direction of travel is improving. For active trading, TWST now has the mix of growth, margin expansion, and clear milestones that can drive strong trend moves and sharp reactions around earnings.

Why Traders Are Watching TWST After The Lilly AI Deal

The latest catalyst is clear: Twist Bioscience locked in an agreement with Eli Lilly’s AI/ML drug discovery platform, TuneLab, to provide antibody characterization data and related services. For TWST, this is not just another contract. It plugs its wet-lab engine directly into a major pharma’s AI models, turning Twist Bioscience’s antibody protocols and data into a core input for Lilly’s discovery pipeline.

Traders saw it right away. TWST shares jumped, with multiple reports showing gains from around 1.5% to more than 4% on the news. That kind of intraday response tells you the market views the Lilly TuneLab partnership as strategically important, not background noise. When a heavyweight like Eli Lilly wires Twist Bioscience into its AI workflow, it validates TWST’s technology and its role in the new drug discovery stack.

Technically, the chart backs up the momentum story. On 2026/09/16, TWST closed at $143.07. The next session, after the Lilly headlines worked through the tape, Twist Bioscience ripped to a high of $163.70 and closed at $159.55. That is a strong range extension and a clean breakout over the prior week’s levels.

Intraday, the 5‑minute chart shows TWST holding above $159 for most of the mid-day session, with buyers stepping in on dips toward the high $150s. That intraday support suggests active traders are defending the move rather than dumping into strength. For TWST momentum players, this is the kind of price action you look for after a real news catalyst: a gap-and-go move that consolidates near the top of the range instead of snapping back.

The story does not stop with Lilly. UBS just initiated coverage on Twist Bioscience with a Neutral rating but a punchy $144 price target, far above the prior consensus of $87.56, while the broader Street remains on a Buy stance. That combination—cautious label, aggressive number—often signals respect for upside even from skeptical analysts. Add in TWST’s AI-designed mini-binder pilot work with Anthropic, which management says is already “probably sort of” embedded in 2027 orders, and traders get a clear message: TWST is central to multiple AI-driven biology plays, but the bar on expectations is already getting higher.

Conclusion

For active traders, Twist Bioscience sits at the intersection of three powerful themes: AI, big pharma partnerships, and a fundamental shift toward profitability. TWST has printed 14 consecutive quarters of revenue growth, expanded gross margins above 50%, and lifted full-year revenue guidance to the $456–457M range. The promise of adjusted EBITDA breakeven in Q4 FY26 gives the stock a clear timeline that traders can trade around.

The Lilly TuneLab agreement turns that narrative into a concrete, high-profile proof point. Twist Bioscience is not just selling synthetic DNA and tools; it is selling the experimental data that powers AI models inside one of the world’s largest drug makers. The stock’s breakout from $143.07 to a $159.55 close, with a $163.70 intraday high on 2026/09/17, shows how quickly sentiment can swing when a catalyst like this hits.

At the same time, TWST is not a free ride. Valuation metrics such as a price-to-sales around 21.2 and negative returns on equity remind traders that Twist Bioscience is still paying the bill for its growth, even as it gets closer to cash-flow break-even. The Anthropic mini-binder work is real, but already baked into longer-term orders, so chasing TWST purely on “AI hype” is risky. That’s why many seasoned day and swing traders lean on process-driven rules and price action instead of wishful thinking. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” Applied to TWST, that means waiting for the chart, volume, and catalysts to align before entering or exiting a trade, rather than assuming every AI headline will translate into a sustainable move.

This is exactly the kind of setup Tim Sykes talks about when he says, “The market rewards preparation, not hope—study the catalysts, learn the patterns, and trade the plan, not the story.” For TWST, the plan now revolves around execution on Lilly TuneLab, maintaining that revenue growth streak, and finally crossing the profitability line—key checkpoints any serious trader should track before making their next move.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!